Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis
Y Ma, M Zhao, Y Liu, D Zhao, L Wang, X Chen, L Li - Hematology, 2019 - Taylor & Francis
Background: Approximately, one-third of adult patients with acute myeloid leukemia (AML)
are refractory to initial induction chemotherapy and relapse occurs in most patients who …
are refractory to initial induction chemotherapy and relapse occurs in most patients who …
The European Medicines Agency Review of Decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific …
M Nieto, P Demolis, E Béhanzin, A Moreau… - The …, 2016 - academic.oup.com
Abstract On September 20, 2012, a marketing authorization valid throughout the European
Union (EU) was issued for decitabine for the treatment of adult patients aged 65 years and …
Union (EU) was issued for decitabine for the treatment of adult patients aged 65 years and …
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
EK Ritchie, EJ Feldman, PJ Christos… - Leukemia & …, 2013 - Taylor & Francis
Abstract Treatment options for older patients with acute myeloid leukemia (AML) and for
patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a …
patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a …
10-day decitabine versus 3+ 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 …
M Lübbert, PW Wijermans, M Kicinski… - The Lancet …, 2023 - thelancet.com
Background Many older patients with acute myeloid leukaemia die or cannot undergo
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …
Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
TM Kadia, S Faderl, F Ravandi, E Jabbour… - Cancer, 2015 - Wiley Online Library
BACKGROUND The treatment of older adults with acute myeloid leukemia (AML) using
standard intensive chemotherapy has been associated with poor outcomes. Effective, less …
standard intensive chemotherapy has been associated with poor outcomes. Effective, less …
[HTML][HTML] The role of hypomethylating agents in the treatment of elderly patients with AML
HK Al-Ali, N Jaekel, D Niederwieser - Journal of geriatric oncology, 2014 - Elsevier
There is a major unmet medical need for treatment options in elderly patients with acute
myeloid leukemia (AML) who are deemed ineligible for intensive treatment. The recent …
myeloid leukemia (AML) who are deemed ineligible for intensive treatment. The recent …
[HTML][HTML] A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
M Lübbert, BH Rüter, R Claus, C Schmoor… - …, 2012 - ncbi.nlm.nih.gov
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still
poses a highly unmet clinical need, and only few large, prospective studies have been …
poses a highly unmet clinical need, and only few large, prospective studies have been …
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC 412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with …
CB Williams, S Kambhampati, W Fiskus… - … : The Journal of …, 2013 - Wiley Online Library
Purpose To determine the preclinical activity, clinical maximum tolerated dose (MTD), and
recommended phase II dose of midostaurin (MS) combined either sequentially or …
recommended phase II dose of midostaurin (MS) combined either sequentially or …
[HTML][HTML] Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of …
P WijerMans, S Suciu, L Baila, U Platzbecker… - Blood, 2008 - Elsevier
Introduction: In 2002 the EORTC and the German MDS Study Group initiated a randomized
phase III study comparing low dose Decitabine to supportive care in patients (pts) of 60 …
phase III study comparing low dose Decitabine to supportive care in patients (pts) of 60 …
[HTML][HTML] Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: a systematic review and meta-analysis
A Stone, T Zukerman, L Flaishon, RB Yakar… - Leukemia Research, 2019 - Elsevier
Older and medically unfit patients with acute myeloid leukaemia (AML) who are unsuitable
for standard induction therapy have limited treatment options. A meta-analysis was …
for standard induction therapy have limited treatment options. A meta-analysis was …